RT Journal Article
SR Electronic
T1 COVID-19 Vaccination in Patients With Multiple Sclerosis on Disease-Modifying Therapy
JF Neurology: Clinical Practice
FD Lippincott Williams & Wilkins
SP 358
OP 361
DO 10.1212/CPJ.0000000000001088
VO 11
IS 4
A1 Andrew Wolf
A1 Enrique Alvarez
YR 2021
UL http://cp.neurology.org/content/11/4/358.abstract
AB The COVID-19 pandemic has resulted in challenges for the practice of neurology. One major concern is how to best manage patients with multiple sclerosis (MS) who are on disease-modifying therapies (DMTs). DMTs frequently have immunosuppressive properties that both increase the risk for COVID-19 and potentially reduce the immunologic response to vaccination in a group already vulnerable to infection due to neurologic deficits. Here, we review early data on COVID-19 outcomes in patients with MS and discuss what is known about vaccine effectiveness in those on anti-CD20 and sphingosine-1-phosphate receptor agents, which are proposed to have attenuating effects based on their mechanisms of action. In addition, we provide recommendations to best use novel COVID-19 vaccines in this population and highlight what information may better inform vaccine strategies in the future.